[{"id":"4325258d-71bf-4423-9ce6-1de5375d6cd1","acronym":"NCI-2020-09704","url":"https://clinicaltrials.gov/study/NCT04640779","created_at":"2025-02-25T12:27:49.994Z","updated_at":"2025-02-25T12:27:49.994Z","phase":"Phase 1","brief_title":"Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT04640779 - NCI-2020-09704","lead_sponsor":"Mayo Clinic","biomarkers":" XPO1","pipe":"","alterations":" ","tags":["XPO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 08/15/2026","primary_completion_date":" 08/15/2026","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2025-02-24"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"0af43381-6afd-4912-9b0c-5801c2007fc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432804","created_at":"2022-06-27T14:54:16.638Z","updated_at":"2025-02-25T16:46:08.151Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","source_id_and_acronym":"NCT05432804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"46612199-ef89-461b-ba2d-66518055f785","acronym":"","url":"https://clinicaltrials.gov/study/NCT05985161","created_at":"2023-08-14T16:10:05.963Z","updated_at":"2025-02-25T16:40:04.331Z","phase":"Phase 2","brief_title":"A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors","source_id_and_acronym":"NCT05985161","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" XPO1","pipe":" | ","alterations":" XPO1 E571K • XPO1 mutation","tags":["XPO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XPO1 E571K • XPO1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2029","primary_completion_date":" 08/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-02-06"},{"id":"b80fb1d9-c22f-4356-804c-6c0a54eb0ff6","acronym":"SENTRY","url":"https://clinicaltrials.gov/study/NCT04562389","created_at":"2021-01-29T07:21:26.651Z","updated_at":"2025-02-25T16:45:11.264Z","phase":"Phase 3","brief_title":"Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis","source_id_and_acronym":"NCT04562389 - SENTRY","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/11/2021","start_date":" 03/11/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-05"},{"id":"f2a77aa2-32ec-4aff-9102-54cfc9c8c2bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06556199","created_at":"2025-02-26T09:23:05.534Z","updated_at":"2025-02-26T09:23:05.534Z","phase":"Phase 1/2","brief_title":"A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma","source_id_and_acronym":"NCT06556199","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/31/2024","start_date":" 08/31/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-08-15"},{"id":"da609c24-a157-41fa-ac07-47f23b043f4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06517511","created_at":"2025-02-26T12:22:33.668Z","updated_at":"2025-02-26T12:22:33.668Z","phase":"Phase 2","brief_title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","source_id_and_acronym":"NCT06517511","lead_sponsor":"Sun Yat-sen University","biomarkers":" TET2 • PTPN2 • DDX3X","pipe":"","alterations":" ","tags":["TET2 • PTPN2 • DDX3X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/11/2024","start_date":" 07/11/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-07-24"},{"id":"74efc10e-be1f-4844-92ec-58390aaca810","acronym":"","url":"https://clinicaltrials.gov/study/NCT05698147","created_at":"2024-06-17T20:38:06.195Z","updated_at":"2024-07-02T16:34:25.656Z","phase":"Phase 1/2","brief_title":"Selinexor in Combination With MTX+Ritu to Treat R/R CNSL","source_id_and_acronym":"NCT05698147","lead_sponsor":"Tong Chen, MD","biomarkers":" IL6 • CXCL13 • IL10","pipe":"","alterations":" ","tags":["IL6 • CXCL13 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-17"},{"id":"f788184e-3946-4215-8882-b92922df8fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436707","created_at":"2021-01-18T11:40:02.216Z","updated_at":"2024-07-02T16:34:26.702Z","phase":"Phase 2","brief_title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","source_id_and_acronym":"NCT02436707","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 10/27/2015","start_date":" 10/27/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"ab8ee1fb-527e-4a1b-957b-d91f218f2a47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05333458","created_at":"2022-04-19T23:53:48.564Z","updated_at":"2024-07-02T16:34:58.762Z","phase":"Phase 2","brief_title":"Testing Atezolizumab With or Without Selinexor in Patients \u003e= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study","source_id_and_acronym":"NCT05333458","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"c1839cbf-613f-4d9e-a411-c798048e613b","acronym":"XPORT-EC-042","url":"https://clinicaltrials.gov/study/NCT05611931","created_at":"2022-11-10T17:01:16.763Z","updated_at":"2024-07-02T16:34:58.758Z","phase":"Phase 3","brief_title":"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05611931 - XPORT-EC-042","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-06-05"},{"id":"ef515d3d-d584-4ab7-90a2-1415e247bfbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04442022","created_at":"2021-01-18T21:22:49.510Z","updated_at":"2024-07-02T16:34:38.119Z","phase":"Phase 2/3","brief_title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04442022","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone"],"overall_status":"Recruiting","enrollment":" Enrollment 501","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-05"},{"id":"77c55f6e-4ff7-43d4-a607-9955ade8f607","acronym":"","url":"https://clinicaltrials.gov/study/NCT05035745","created_at":"2021-09-05T15:55:43.795Z","updated_at":"2024-07-02T16:35:02.873Z","phase":"Phase 1/2","brief_title":"Selinexor \u0026 Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","source_id_and_acronym":"NCT05035745","lead_sponsor":"National University Hospital, Singapore","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-05-17"},{"id":"cc43e353-d912-4b11-8947-43a4ef4b102a","acronym":"SINE","url":"https://clinicaltrials.gov/study/NCT02199665","created_at":"2021-01-18T10:17:08.750Z","updated_at":"2024-07-02T16:35:03.805Z","phase":"Phase 1","brief_title":"Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT02199665 - SINE","lead_sponsor":"University of Chicago","biomarkers":" CRBN","pipe":"","alterations":" ","tags":["CRBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/12/2014","start_date":" 06/12/2014","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/25/2024","study_completion_date":" 12/25/2024","last_update_posted":"2024-05-14"},{"id":"f337b20f-bcf2-469a-aab5-14a60c90ec2d","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT04256707","created_at":"2021-01-18T20:41:24.594Z","updated_at":"2024-07-02T16:35:05.435Z","phase":"Phase 1/2","brief_title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","source_id_and_acronym":"NCT04256707 - SPRINT","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • 5-fluorouracil • irinotecan • Xpovio (selinexor) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/14/2020","start_date":" 01/14/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-07"},{"id":"9c1f7fff-bdbd-42f6-b86e-29192b0576bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05850286","created_at":"2023-05-09T14:04:26.586Z","updated_at":"2024-07-02T16:35:18.522Z","phase":"Phase 2","brief_title":"A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities","source_id_and_acronym":"NCT05850286","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" TP53 • SDC1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-02-20"},{"id":"1f17a218-bc5e-4d55-a40a-94144604e122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02323880","created_at":"2021-01-18T11:01:20.161Z","updated_at":"2024-07-02T16:35:24.780Z","phase":"Phase 1","brief_title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","source_id_and_acronym":"NCT02323880","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 10/30/2015","start_date":" 10/30/2015","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-01-01"},{"id":"8f3a4a5a-f465-4be9-88b8-05e3ac3cf7a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05577364","created_at":"2023-12-14T18:18:10.664Z","updated_at":"2024-07-02T16:35:26.238Z","phase":"Phase 1/2","brief_title":"Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients","source_id_and_acronym":"NCT05577364","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1 • PD-1 • TET2 • LAG3 • CTLA4 • PTPN2 • DDX3X","pipe":" | ","alterations":" TET2 mutation • PTPN2 mutation","tags":["PD-L1 • PD-1 • TET2 • LAG3 • CTLA4 • PTPN2 • DDX3X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TET2 mutation • PTPN2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor) • vincristine • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2023-12-14"},{"id":"a7b10d24-6834-4ab0-b432-bed5ee7f3e42","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062641","created_at":"2023-10-02T20:12:32.544Z","updated_at":"2024-07-02T16:35:30.152Z","phase":"Phase 2","brief_title":"Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL","source_id_and_acronym":"NCT06062641","lead_sponsor":"Ruijin Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xpovio (selinexor) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2023-11-07"},{"id":"2d1c3ca8-7296-43e4-82a1-3a09a7010bbd","acronym":"C-SMART","url":"https://clinicaltrials.gov/study/NCT04534725","created_at":"2021-01-18T21:42:26.535Z","updated_at":"2024-07-02T16:35:39.087Z","phase":"Phase 3","brief_title":"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","source_id_and_acronym":"NCT04534725 - C-SMART","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • LENZ (lenzilumab)"],"overall_status":"Completed","enrollment":" Enrollment 441","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 04/19/2023","study_completion_date":" 04/19/2023","last_update_posted":"2023-08-24"},{"id":"1f16bee8-6e15-4dae-b6f9-9aa78162bd60","acronym":"","url":"https://clinicaltrials.gov/study/NCT05974085","created_at":"2023-08-03T15:09:42.667Z","updated_at":"2024-07-02T16:35:41.106Z","phase":"Phase 2","brief_title":"XPO-1 in Combination With RCHOP for DH/TH Lymphoma","source_id_and_acronym":"NCT05974085","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-08-03"},{"id":"88ee1cce-5bb4-4a71-bc22-a9d0386b5877","acronym":"","url":"https://clinicaltrials.gov/study/NCT04856189","created_at":"2021-04-23T22:52:40.697Z","updated_at":"2024-07-02T16:35:44.101Z","phase":"Phase 1/2","brief_title":"Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT04856189","lead_sponsor":"Mamta Parikh","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-07-03"}]